Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.67 is 75% above its 5-year average of -6.71, near the high end of its 5-year range (-12.80–-1.48).
As of the fiscal period ended Wednesday, December 31, 2025. 54.37% above its 12-month average of -3.66.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.06.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 24 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:08:42.250Z. Historical observations retain their original dates. Historical series through 2025-08-14.
EARNINGS PER SHARE (EPS)
-1.67
EARNINGS PER SHARE (EPS) AVG TTM
-3.66
EARNINGS PER SHARE (EPS) AVG 3Y
-8.03
EARNINGS PER SHARE (EPS) AVG 5Y
-6.71
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+54.37%
CURRENT VS 3Y AVG
+79.20%
CURRENT VS 5Y AVG
+75.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Unicycive Therapeutics, Inc.
Market Cap
$112.94M
Earnings Per Share (EPS)
-1.67
TTM Avg
-3.66
3Y Avg
-8.03
5Y Avg
-6.71
Market Cap
$112.57M
Earnings Per Share (EPS)
-1.08
TTM Avg
-1.62
3Y Avg
-1.56
5Y Avg
-1.43
Market Cap
$113.77M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.13
3Y Avg
-1.07
5Y Avg
-0.91
Market Cap
$113.89M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
Market Cap
$114.46M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.87
3Y Avg
-1.14
5Y Avg
-0.92
Market Cap
$110.30M
Earnings Per Share (EPS)
-3.21
TTM Avg
-1.79
3Y Avg
-1.14
5Y Avg
-1.14
Market Cap
$115.67M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.38
3Y Avg
-1.93
5Y Avg
-2.07
Market Cap
$109.14M
Earnings Per Share (EPS)
-1.52
TTM Avg
-3.16
3Y Avg
-3.35
5Y Avg
-6.72
Market Cap
$116.76M
Earnings Per Share (EPS)
-0.33
TTM Avg
-0.41
3Y Avg
-0.34
5Y Avg
-0.29
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $112.94M | -1.67 | -3.66 | -8.03 | -6.71 |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -1.08 | -1.62 | -1.56 | -1.43 |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -1.07 | -1.13 | -1.07 | -0.91 |
| Genelux Corporation (GNLX)vs › | $113.89M | -0.89 | -0.91 | -0.79 | -0.74 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -0.47 | -0.87 | -1.14 | -0.92 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | -3.21 | -1.79 | -1.14 | -1.14 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -0.99 | -1.38 | -1.93 | -2.07 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | -1.52 | -3.16 | -3.35 | -6.72 |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -0.33 | -0.41 | -0.34 | -0.29 |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -40.87 | -73.79 | -78.14 | -71.60 |
Trailing EPS (TTM)
$-1.67
Forward EPS (Est.)
$-1.26
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.67 |
| 2024-12-31 | -5.65 |
| 2023-12-31 | -12.80 |
| 2022-12-31 | -11.99 |
| 2021-12-31 | -6.68 |
| 2020-12-31 | -1.48 |
| 2019-12-31 | -1.42 |
| 2018-12-31 | -0.73 |
